Curious reaction to intrathecal chemotherapy

Samantha Lisa Forner, Jessica Gough, Christos Mikropoulos

Department of Oncology, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK

Correspondence to
Dr Samantha Lisa Forner, samantha.forner@nhs.net

SLF and JG contributed equally.

Accepted 2 December 2018

DESCRIPTION

A 23-year-old woman with a diagnosis of diffuse large B-cell lymphoma presented with an area of erythema and discomfort in her lower back after administration of intrathecal chemotherapy (figure 1).

She originally presented with a 4-month history of back pain with leg weakness. MRI confirmed a pathological fracture at L3 which was encroaching into the spinal canal. She was treated for an impending cauda equina compression with a single 8Gy fraction of palliative radiotherapy, delivered to L2–L4 (figure 2). Subsequent investigations were consistent with disseminated diffuse large B-cell lymphoma.

After initially being treated with R-CHOP chemotherapy, she was commenced on R-CODOX-M 6 weeks after completion of radiotherapy. She received intrathecal methotrexate as per the planned regime. Within a few hours, an abnormal area inferior to the intrathecal site was noted. This was initially attributed to extravasation. As the lesion further developed, advice from the oncology team was sought.

On examination, there was a well-demarcated rectangular patch of erythematous skin and one area of moist desquamation found in the midline of the lumbar spine, consistent with a diagnosis of radiation recall. Differential diagnoses included extravasation, contact dermatitis, eczematous reaction or other de novo skin pathology (ie, Bowen’s disease).

A diagnosis of dressing-induced contact dermatitis was excluded due to being able to visualise the intrathecal site distal to this region and determining that the location of the dressing was therefore also distal to this (in addition to a different shape). For this reason, extravasation could also be excluded. Erythema, moist desquamation and warmth, clinically indicate a skin inflammation and reaction, and with the uniform shape seen, this shape thereby raised the suspicion of radiation recall (rather than a de novo skin lesion or eczema). Her radiotherapy plan was reviewed and the area of skin reaction corresponded precisely to the area previously treated, with the location, size and shape matching the measurements documented on the reviewed radiotherapy plan.

General supportive advice was given for the skin reaction (eg, regular emollients and dressings as required). With these conservative measures, the reaction improved and subsequently resolved.

Radiation recall is a recognised complication of radiotherapy in up to 6% of patients, in which patients can experience delayed acute...
inflammation of the skin within the field of previous irra-
diation. This is thought to be triggered by chemotherapy,
more commonly described with anthracyclines, antimetab-
olites, taxanes and methotrexate. Radiation recall can be
distinguished from acute radiotherapy toxicity according to
the time of onset, >7 days or <7 days respectively with
a median time of 39 days. Pathophysiology is not yet
proven.

Acknowledgements Andrew Brown - Macmillan Clinical Nurse Specialist for
Acute Oncology Services at Maidstone Hospital

Contributors All authors have had equal participation in co-authoring and
reviewing of article. SLF and JG: planned, concepted and designed project, performed
acquisition and analysis of evidence, wrote and reviewed report. CM: planned
and designed project, reviewed, revised and critically appraised project; provided
supervision and guidance with final approval.

Funding The authors have not declared a specific grant for this research from any
funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
1. Burris HA, Hurtig J. Radiation recall with anticancer agents. Oncologist
dermatitis (rrd) after hypericin therapy—case report and review of the literature.
Radiat Oncol 2006;1:32.